Biorce, a Barcelona-based health AI company focused on using artificial intelligence to improve how clinical trials are designed and executed, announced it has closed a $52.5 million Series A round to accelerate international expansion and scale its platform, Aika.
The company said the financing included new investment from DST Global Partners, with existing backers Norrsken VC and YZR Capital increasing their participation. The round also included participation from Mustard Seed Maze and Endeavor Catalyst, according to the company.
Biorce characterized the raise as the largest Series A to date in the Iberian healthtech and AI ecosystem, and said the deal brings its total funding to more than $60 million. The company also pointed to a recent fundraising cadence that included €3.5 million raised in November 2024 and a €5 million extension in summer 2025, describing the quick progression to a larger Series A as a sign of investor conviction in its technology, execution, and longer-term market opportunity.
The company is positioning Aika as an AI-driven protocol intelligence system designed to reduce clinical trial delays and costs by anticipating risks earlier in trial design and execution. Biorce cited industry estimates of significant global spend on clinical trials management and said it is targeting a persistent problem in the traditional process: protocol amendments that can pause recruitment for weeks and add substantial costs, often after regulators request clarifications or additional changes.
Biorce said its platform is built on a data foundation spanning 1 million clinical trials and is intended for pharmaceutical companies, biotech firms, and contract research organizations. The company said the system is designed to help teams justify trial design decisions to regulators, including the FDA and the European Medicines Agency, with the goal of reducing downstream rework and shortening timelines without sacrificing scientific rigor or patient safety.
In addition to institutional investors, the company said the round included angel participation from a group of European technology founders and executives, including the chief executive of Revolut and the co-founder and chief executive of Mistral AI, among others.
Looking ahead, Biorce said it plans to expand headcount to 250 employees by the end of 2026 and is preparing to launch a development and R&D hub in Austin as part of a broader push to strengthen its U.S. presence. The company also said it is finalizing a move to larger offices in Barcelona, in a site it described as formerly AstraZeneca’s headquarters in the city.
For 2026, the company said near-term priorities include strengthening Aika’s protocol intelligence capabilities and adding new modules, including tools for contract management and negotiation, as well as features intended to support budget negotiation and operational planning. Biorce said the platform is already being used across multiple therapeutic areas, including oncology, neurology, and rare diseases, and described its approach as therapy-agnostic to enable scaling across a broad range of clinical programs.
KEY QUOTES
“Our mission is to make clinicaltrials faster, more reliable, and more accessible, so patients can benefit from new treatments sooner.”
“This $52 million round reflects both the scale of the problem we are addressing and the market’s confidence in our vision. Clinical trial delays and inefficiencies cost time, money, and ultimately lives. Our mission is to make trials faster, more reliable, and more accessible, so patients can benefit from new treatments sooner. The speed at which we have raised capital since our last round in July 2025 is a strong validation of our technology, our team, and the impact we can generate.”
Pedro Coelho, CEO of Biorce
“From our very first meeting, we had strong conviction in Pedro and the team’s ability to build a leading global AI platform for clinical trials, and their execution has exceeded our expectations. The platform is already seeing strong global demand, proving it can materially reduce timelines and costs for pharma and, more importantly, bring new treatments to patients faster than previously possible. That’s why we’re excited to double down on our investment. Their expansion into the U.S. is a natural next step and further cements the company’s trajectory toward becoming a category-defining force in clinical research.”
Tove Larsson, General Partner at Norrsken VC, Board Member
“When we backed Biorce in its first institutional round in 2024, we quickly built strong conviction in Pedro’s bold vision to transform how clinical trials are designed and run. That conviction was reinforced by the clear and urgent need we saw across the market for a solution like Aika. It became evident early on that Pedro is building toward a billion-dollar opportunity in PharmaTech — one we were eager to be part of. Seeing this early conviction materialize so rapidly is incredibly exciting. Due to the exceptional development of the company since our first investment, we are convinced that Biorce will become the global leader in this space, delivering meaningful time and cost savings for pharma companies worldwide. We’re delighted to invest again in this round and look forward to continuing this journey together.“
Markus Feuerecker, General Partner at YZR Capital, Board Member, and Lead Investor in Biorce’s Seed round
